Brief: FDA Approves Ziihera For Her2+ Advanced Gastroesophageal Cancer
25/08/2026 18:11
BRIEF-FDA Approves Ziihera For Her2+ Advanced Gastroesophageal Cancer Aug 25 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O:
U.S. FDA APPROVES ZIIHERA® (ZANIDATAMAB-HRII) WITH AND WITHOUT TISLELIZUMAB PLUS CHEMOTHERAPY IN FIRST-LINE HER2+ ADVANCED GASTROESOPHAGEAL ADENOCARCINOMA
JAZZ PHARMACEUTICALS - ZIIHERA U.S. PRESCRIBING INFORMATION INCLUDES BOXED WARNINGS FOR DIARRHEA AND EMBRYO-FETAL TOXICITY
Source text: ID:nPn7tW0dHa
Further company coverage: JAZZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032